CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Immunotherapy in multiple myeloma.
Immunotherapy in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤患者在接受现有主要药物类别——免疫调节剂、蛋白酶体抑制剂和抗CD38抗体——治疗后出现难治性疾病或复发时，缺乏令人满意的治疗选择。基于重定向T淋巴细胞使其直接作用于肿瘤细胞的新疗法，如双特异性抗体和CAR-T 细胞，正在改变这一局面。已发表的信息证实，这些药物在难治性骨髓瘤患者中具有前所未有的抗肿瘤活性，在不久的将来，它们必将成为这些患者治疗的支柱。然而，这些疗法也具有特定的特征以及中期或长期毒性，带来了新的医疗挑战。在这篇综述中，我们探讨了这些治疗在复发/难治性多发性骨髓瘤患者中应用的当前结果和未来挑战。
Patients with multiple myeloma who present with refractory disease or relapse after receiving the main classes of available drugs -immunomodulators, proteasome inhibitors and antibodies against CD38- do not have satisfactory therapeutic alternatives.
New treatments based on the redirection of T lymphocytes to act directly against tumor cells, such as bispecific antibodies and T cells with chimeric antigen receptors, are changing this scenario. The published information confirms unprecedented antitumor activity of these agents in patients with refractory myeloma and they will certainly represent the backbone of the treatment of these patients in the immediate future.
However, these therapies also present specific characteristics and medium or long-term toxicities that pose new healthcare challenges. In this review, we address the current results and future challenges of the administration of these treatments in patients with relapsed or refractory multiple myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
